

**2021 Antibiogram Outpatient Providers (January-December)**

Relative Cost Per Day PO/IV <sup>2</sup>	\$	\$	\$	\$	\$	\$
<b>Gram Negative Organisms</b>						
Legend:						
• Susceptible Reported as %						
• (Maximum # strains tested)						
↑ > 5% increase in Susceptibility from Previous Year						
↓ > 5% decrease in Susceptibility from Previous Year						
	Cefazolin <sup>3</sup>	Ceftriaxone	Ciprofloxacin	Levofloxacin	Trimethoprim/ sulfa	Nitrofurantoin Urinary Tract Infections only
<i>Escherichia coli</i> (2191)	94 <sup>3</sup>	96	90	90	86	97
<i>Enterobacter species</i> (161)	0	85	99	98	93	25
<i>Klebsiella species</i> (476)	91 <sup>3</sup>	93	93	94	88	37
<i>Proteus species</i> (189)	98 <sup>3</sup>	99	91	92	90	0
<i>Pseudomonas aeruginosa</i> (187)	-	-	94	89	-	-

Relative Cost Per Day PO/IV <sup>2</sup>	\$	\$	\$	\$	\$	\$\$\$	\$	\$	\$	\$	\$	\$	\$
<b>Gram Positive Organisms</b>													
Legend:													
• Susceptible Reported as %													
• (Maximum # strains tested)													
↑ > 5% increase in Susceptibility from Previous Year													
↓ > 5% decrease in Susceptibility from Previous Year													
	Ceftriaxone Non-meningitis	Ceftriaxone Meningitis	Clindamycin	Erythromycin	Levofloxacin	Linezolid	Oxacillin <sup>4</sup>	Penicillin	Penicillin Non-meningitis	Penicillin Meningitis	Tetracycline	Trimethoprim/ sulfa	Nitrofurantoin Urinary Tract Infections only
Methicillin Susceptible Staphylococcus aureus <sup>4</sup> (454)	-	-	78	66	91	100	100	0	-	-	93	97	98
Methicillin Resistant Staphylococcus aureus <sup>4</sup> (228)	-	-	76	14	54	100	0	0	-	-	98	84	18/18
Staphylococcus coagulase negative (358)	-	-	64↓	47↓	70	100	54	0	-	-	83	72↓	100
Enterococcus faecalis (225)	-	-	-	-	76	100	-	99	-	-	-	-	100
Enterococcus faecium <sup>5</sup> (42)	-	-	-	-	7/42	42/42	-	10/42	-	-	-	-	4/33
Streptococcus pneumoniae <sup>5</sup> (31)	31/31	25/31	28/31	18/31	31/31	31/31	-	-	29/31	22/31	28/31	-	-
Streptococcus agalactiae (Group B) <sup>5</sup> (27)	-	-	9/27	8/25	26/27	27/27	-	26/26	-	-	-	-	-

- All data presented includes Springfield Hospital population.
- Relative Total Cost per Day PO/IV for Treatment: Green = Least expense, Red = Most expense
- All data presented includes Springfield Hospital population.
- Cannot differentiate Cefazolin Susceptible from Intermediate categories by testing method on non urinary tract specimens. Results valid only when used as therapy for uncomplicated UTI for *Escherichia coli*, *Klebsiella pneumoniae* or *Proteus mirabilis*.
- Oxacillin is tested as a surrogate for methicillin and nafcillin
- Trend assessment not provided due to low number of isolates.